Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Safety Study of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor in Subjects With Rheumatoid Arthritis [Phase 3b/4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in Comparison to A Tumor Necrosis Factor (TNF) Inhibitor in Subjects with Rheumatoid Arthritis
Category & Conditions: Immune System Diseases and Conditions
Medicine: XELJANZ®(TOFACITINIB)
ClinicalTrials.gov Identifier (NCT): NCT02092467
Protocol ID: A3921133
PrintDownloadOpen Plain Language Summary Result: Click here